Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 181.84M P/E - EPS this Y 55.10% Ern Qtrly Grth -
Income -61.58M Forward P/E -1.91 EPS next Y -27.30% 50D Avg Chg -23.00%
Sales 1.51M PEG - EPS past 5Y - 200D Avg Chg -48.00%
Dividend N/A Price/Book 2.81 EPS next 5Y - 52W High Chg -75.00%
Recommedations 1.20 Quick Ratio 13.04 Shares Outstanding 206.53M 52W Low Chg 2.00%
Insider Own 0.26% ROA -23.34% Shares Float 150.27M Beta 1.01
Inst Own 72.77% ROE -41.49% Shares Shorted/Prior 10.07M/11.56M Price 0.88
Gross Margin 100.00% Profit Margin - Avg. Volume 1,368,141 Target Price 7.33
Oper. Margin -2,467.42% Earnings Date Jun 27 Volume 570,730 Change -1.70%
VistaGen Therapeutics, Inc. News
06/23/22 VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates
06/23/22 VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
06/22/22 VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
06/17/22 VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022
06/02/22 VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
05/31/22 Nurix Therapeutics, Inc. (NRIX) Soars 14.5%: Is Further Upside Left in the Stock?
05/27/22 VistaGen to Participate in Upcoming June Investor Conferences
05/19/22 7 Cheap Biotech Stocks to Buy Now
05/10/22 What You Need To Know About VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) Investor Composition
05/05/22 VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder
05/02/22 VistaGen Appoints Reid Adler as Chief Legal Officer
04/21/22 VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
04/12/22 Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC
04/12/22 Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
04/12/22 VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
04/07/22 Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer
04/05/22 Bristol Myers (BMY) Gets EC Nod for Opdivo's Label Expansion
03/24/22 VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference
03/19/22 We're Hopeful That VistaGen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.

VTGN Chatroom

User Image BinaryLogic Posted - 2 hours ago

$VTGN The Palisade-1/2 trials (Phs-3) studies are concluding and data/results will be made available in 2H-2022. The stock is now trading well-under $1.00 now at a 12mo low, but the potential here is very strong, 2H-2022 (IMO). PH94B is specifically evaluated in Palisade to address SAD; however, there are many other applications for this drug and its variations beyond that. I drew my average under $1.00, and now I will wait for data/results in 2H-2022. https://www.businesswire.com/news/home/20220622005431/en/VistaGen-Announces-Completion-of-PALISADE-1-Phase-3-Clinical-Study-of-PH94B-for-the-Acute-Treatment-of-Social-Anxiety-Disorder

User Image KRSONEBDP Posted - 8 hours ago


User Image veargogan Posted - 8 hours ago

$VTGN Does anyone have by way of analogy to another start up bio how a ramp up leading to a Phase 3 announcement looks like?

User Image MindMedOG Posted - 8 hours ago

$VTGN do we know if our spray is addictive or not

User Image shortvolumes Posted - 9 hours ago

Short sale volume (not short interest) for $VTGN on 2022-06-29 is 58%. http://shortvolumes.com/?t=VTGN via @shortvolumes

User Image sumset1965 Posted - 10 hours ago

$VTGN OK. I have a question. Why is everyone bitching and panicking here day after day, when the phase 3 results are not even coming for a couple of months? That's how bio works: Dead for some time, and then Boom! Let's see what happens before we start committing suicide. LOL.

User Image C_H Posted - 10 hours ago

$VTGN just took out 10 shares short

User Image C_H Posted - 10 hours ago

$VTGN give me a .90 or higher close

User Image C_H Posted - 12 hours ago

$VTGN Stupid volume in the 1.10-1.20 a few months ago. Then it had its big run up. I’m quite confident that was big funds gobbling up at the same time.

User Image C_H Posted - 12 hours ago

$VTGN this seems to be good support. It love .90

User Image I_AM_GROOT Posted - 14 hours ago

$VTGN I'm sensing buyout.. Would make sense how this is trading..

User Image OriginalTradeonrumor Posted - 14 hours ago

$VTGN Gotta hold .86!!! Can’t close below it 🙏🙏🙏🙏🙏🙏🙏🙏🙏

User Image themainewoodsman Posted - 14 hours ago

$VTGN last I looked this was in the mid 3s, dam

User Image Arnold75 Posted - 15 hours ago

$VTGN This think, really likes fking with us 🙄

User Image C_H Posted - 15 hours ago

$VTGN well, looks like I’ll be a gambling man going into August

User Image doitnow182 Posted - 16 hours ago

$VTGN dont get your hopes up...most biotechs fail, even with approval...see trvn and kmph

User Image sistermojo Posted - 16 hours ago

$VTGN I hope this doesn't turn out like $TRVN

User Image Arnold75 Posted - 18 hours ago

$VTGN Happy Fk u Friday…

User Image OriginalTradeonrumor Posted - 1 day ago

$VTGN Ok so we barcoded a bit today as was the potential I noted in my earlier text Looking for an upside breakout and continued upward trend starting very soon until P3 mid August announcement What’s happening now is typical movement of a stock that will follow this track Stay steady…add down here…soon to be rewarded!

User Image C_H Posted - 1 day ago

$VTGN Phase 3 readout to be released in August. On demand anxiety nasal spray with novel mechanism 🔫💰🚨. Billion dollar market looking to take over benzos like Xanax. $SPY $XBI

User Image Doncicc0627 Posted - 1 day ago

$VTGN can’t wait these next 3 months are gonna be fun 😁

User Image stevec2o Posted - 1 day ago

$VTGN idiot

User Image doitnow182 Posted - 1 day ago

$VTGN It's Friday night...and Vistagen failed on the west side.

User Image Zydecoshuffle Posted - 1 day ago

$VTGN wow, we went down 1/10,000 th of a penny . Wtf ?

User Image tickeron Posted - 1 day ago

How does this make you feel? $VTGN in -7.5% Downtrend, declining for three consecutive days on June 28, 2022. View odds for this and other indicators: https://srnk.us/go/3795287

User Image Jeffmids Posted - 1 day ago

$VTGN The destruction continues on just about everything -contemplating selling my other failing shares and buying VTGN as still feel this has much more potential for a recovery .

User Image doitnow182 Posted - 1 day ago

$VTGN worth less than a can of soda

User Image Arnold75 Posted - 1 day ago

$VTGN look on the bright side… there’s always, Fk u Friday 🤬

User Image printcomm Posted - 1 day ago

$VTGN Let's hope for EOD action to the upside like yesterday...altho it doesn't really matter.

User Image veargogan Posted - 1 day ago

$VTGN And ...

Analyst Ratings
Baird Outperform May 20, 21
Jefferies Buy Feb 18, 21
William Blair Outperform Jan 4, 21
Aegis Capital Buy Oct 8, 20
William Blair Outperform Aug 28, 19
Chardan Capital Neutral Jul 22, 19
Maxim Group Buy Jun 27, 18
Oppenheimer Outperform May 24, 18
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Singh Shawn CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER May 12 Option 1 100,000 100,000 148,998 05/16/22
DOTSON JERROLD DUANE VP, CFO AND SECRETAR.. VP, CFO AND SECRETARY Jan 11 Option 1 18,750 18,750 94,571 01/12/22